BMC Gastroenterology (Jul 2021)

Study protocol P-MAPS: microbiome as predictor of severity in acute pancreatitis—a prospective multicentre translational study

  • C. Ammer-Herrmenau,
  • T. Asendorf,
  • G. Beyer,
  • S. M. Buchholz,
  • S. Cameron,
  • M. Damm,
  • F. Frost,
  • R. Henker,
  • R. Jaster,
  • V. Phillip,
  • M. Placzek,
  • C. Ratei,
  • S. Sirtl,
  • T. van den Berg,
  • M. J. Weingarten,
  • J. Woitalla,
  • J. Mayerle,
  • V. Ellenrieder,
  • A. Neesse

DOI
https://doi.org/10.1186/s12876-021-01885-4
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Background Acute pancreatitis (AP) is an inflammatory disorder that causes a considerable economic health burden. While the overall mortality is low, around 20% of patients have a complicated course of disease resulting in increased morbidity and mortality. There is an emerging body of evidence that the microbiome exerts a crucial impact on the pathophysiology and course of AP. For several decades multiple clinical and laboratory parameters have been evaluated, and complex scoring systems were developed to predict the clinical course of AP upon admission. However, the majority of scoring systems are determined after several days and achieve a sensitivity around 70% for early prediction of severe AP. Thus, continued efforts are required to investigate reliable biomarkers for the early prediction of severity in order to guide early clinical management of AP patients. Methods We designed a multi-center, prospective clinical-translational study to test whether the orointestinal microbiome may serve as novel early predictor of the course, severity and outcome of patients with AP. We will recruit 400 AP patients and obtain buccal and rectal swabs within 72 h of admission to the hospital. Following DNA extraction, microbiome analysis will be performed using 3rd generation sequencing Oxford Nanopore Technologies (ONT) for 16S rRNA and metagenomic sequencing. Alpha- and beta-diversity will be determined and correlated to the revised Atlanta classification and additional clinical outcome parameters such as the length of hospital stay, number and type of complications, number of interventions and 30-day mortality. Discussion If AP patients show a distinct orointestinal microbiome dependent on the severity and course of the disease, microbiome sequencing could rapidly be implemented in the early clinical management of AP patients in the future. Trial registration: ClinicalTrials.gov Identifier: NCT04777812

Keywords